Mulga snake (Pseudechis australis) envenoming: A spectrum of myotoxicity, anticoagulant coagulopathy, haemolysis and the role of early antivenom therapy-Australian Snakebite Project (ASP-19)

Christopher Johnston, Simon Brown, Margaret O'Leary, Bart Currie, R Greenburg, Michael Taylor, Chris Barnes, J White, Geof Isbister

    Research output: Contribution to journalArticle

    Abstract

    Context: Mulga snakes (Pseudechis australis) are venomous snakes with a wide distribution in Australia. 

    Objective: The objective of this study was to describe mulga snake envenoming and the response of envenoming to antivenom therapy. 

    Materials and methods: Definite mulga bites, based on expert identification or venom-specific enzyme immunoassay, were recruited from the Australian Snakebite Project. Demographics, information about the bite, clinical effects, laboratory investigations and antivenom treatment are recorded for all patients. Blood samples are collected to measure the serum venom concentrations pre- and post-antivenom therapy using enzyme immunoassay. 

    Results: There were 17 patients with definite mulga snake bites. The median age was 37 years (6–70 years); 16 were male and six were snake handlers. Thirteen patients had systemic envenoming with non-specific systemic symptoms (11), anticoagulant coagulopathy (10), myotoxicity (7) and haemolysis (6). Antivenom was given to ten patients; the median dose was one vial (range, one–three vials). Three patients had systemic hypersensitivity reactions post-antivenom. Antivenom reversed the coagulopathy in all cases. Antivenom appeared to prevent myotoxicity in three patients with high venom concentrations, given antivenom within 2 h of the bite. Median peak venom concentration in 12 envenomed patients with samples was 29 ng/mL (range, 0.6–624 ng/mL). There was a good correlation between venom concentrations and the area under the curve of the creatine kinase for patients receiving antivenom after 2 h. Higher venom concentrations were also associated with coagulopathy and haemolysis. Venom was not detected after antivenom administration except in one patient who had a venom concentration of 8.3 ng/ml after one vial of antivenom, but immediate reversal of the coagulopathy. 

    Discussion: Mulga snake envenoming is characterised by myotoxicity, anticoagulant coagulopathy and haemolysis, and has a spectrum of toxicity that is venom dose dependant. This study supports a dose of one vial of antivenom, given as soon as a systemic envenoming is identified, rather than waiting for the development of myotoxicity.

    Original languageEnglish
    Pages (from-to)417-424
    Number of pages8
    JournalClinical Toxicology
    Volume51
    Issue number5
    DOIs
    Publication statusPublished - 1 Jun 2013

    Fingerprint Dive into the research topics of 'Mulga snake (Pseudechis australis) envenoming: A spectrum of myotoxicity, anticoagulant coagulopathy, haemolysis and the role of early antivenom therapy-Australian Snakebite Project (ASP-19)'. Together they form a unique fingerprint.

  • Cite this